Brief: SSY Group Obtains NMPA Approval For Safinamide Mesylate Tablets
22/06/2026 05:02
BRIEF-SSY Group Obtains NMPA Approval For Safinamide Mesylate Tablets June 22 (Reuters) - SSY Group Ltd 2005.HK:
OBTAINS NMPA APPROVAL FOR SAFINAMIDE MESYLATE TABLETS
OBTAINS NMPA APPROVAL FOR PROCATEROL HYDROCHLORIDE INHALATION SOLUTION
Further company coverage: 2005.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on SSY
See all newsBrief: SSY Group Receives NMPA China Approval For Sodium Cromoglicate Eye Drops 2%
Brief: SSY Group Obtains NMPA Approval For Nimodipine Oral Solution
Brief: SSY Group Appoints Wu Heng Yao As Executive Director
Brief: SSY Group Says Ziprasidone Mesilate Receives Registration Approval In China
Hong Kong's SSY Group H1 profit rises on infusion solutions growth